Remedium Bio Announces Successful $2.3M Expanded Seed Raise
08/15/22, 12:35 PM
Location
bostonMoney raised
$2.3 million
Industry
therapeutics
biotechnology
health care
Round Type
seed
Remedium Bio, Inc., a biotechnology company developing novel gene therapies, today announced that it has closed more than $2.3M in its expanded seed round financing. Funding from the raise is being used to study Remedium's lead product, a single-injection gene therapy potentially capable of reversing cartilage loss, in a collaboration with Tufts University School of Medicine scientists researching rheumatic disorders. The financing was led by Sherwood Ventures and included participation from, LongevityTech.Fund, Primo Medical Group, Angel Star Ventures, Apis Health Angels, MicroVentures, and Guindy Alumni Angels.
Company Info
Location
boston, massachusetts, united states
Additional Info
Remedium Bio is a gene therapy company focused on the development of treatments for large unmet clinical needs. To enable this, we developed a revolutionary gene therapy platform technology, which enables safe, effective, and durable delivery of therapeutic genes while allowing for simple post-treatment dose adjustment. The Prometheus™ adjustable gene therapy platform is able to safely and durably replace multi-injection subcutaneously administered biologics, with a single treatment, at a fraction of the cost, and without genetic integration. Our lead product is a disease-modifying treatment for Osteoarthritis that is based on the only clinically validated chondro-regenerative mechanism. Remedium’s pipeline includes gene therapy treatments in the fields of Weight Loss, Type 2 Diabetes, and Stroke.